LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that since the market introduction of ZYFLO CRTM (zileuton) extended-release tablets on September 27, 2007, average weekly prescriptions of ZYFLO CR and ZYFLO® (zileuton tablets) for the four week period ending February 1, 2008 have increased approximately 43 percent compared to the four week period ending September 28, 2007. In addition, the number of active prescribers, or physicians who have prescribed ZYFLO CR and ZYFLO on a weekly basis, has grown more than 50 percent. Approximately 1,500 physicians have initiated therapy with ZYFLO CR since launch.
